Expanding Epinephrine Options to Enhance Anaphylaxis Care

The landscape of anaphylaxis care is evolving rapidly, particularly regarding the delivery of epinephrine. A recent panel discussion explored the expanding range of options available, focusing on how these developments can eliminate long-standing barriers to timely treatment. Experts reviewed both existing products and emerging alternatives that have the potential to transform how patients manage severe allergic reactions.

Current and Emerging Epinephrine Options

In the United States, epinephrine autoinjectors are available in dosages of 0.1 mg, 0.15 mg, and 0.3 mg. A 0.5 mg autoinjector is currently available in Europe but not yet approved for use in the US. Dr. David Golden of Johns Hopkins University raised concerns about the implications of underdosing larger adults, emphasizing the importance of administering a second 0.3 mg dose if symptoms do not improve. He noted that using weight-based dosing (0.01 mg/kg), a 0.3 mg dose is suitable for patients weighing approximately 30 kg (66 pounds), highlighting the need for repeat doses in adolescents and adults experiencing severe allergic reactions.

The panelists also reaffirmed that while syringe-and-needle intramuscular epinephrine is still appropriate in healthcare settings for precise dosing, autoinjectors provide faster absorption, as supported by pharmacokinetic studies. Despite these advancements, many barriers to effective anaphylaxis treatment remain rooted in human factors. Issues such as fear of needles, reluctance to carry devices, uncertainty about diagnosis, and hesitation to use epinephrine early contribute to poor outcomes.

New Non-Injectable Options

During the discussion, experts highlighted the significance of newly approved and emerging non-injectable options. One notable product is the first FDA-approved intranasal epinephrine spray, known as Neffy, which has been on the market for over a year. This approval was based on pharmacokinetic data showing plasma epinephrine levels comparable to existing intramuscular products, as conducting placebo-controlled anaphylaxis trials is not feasible. The nasal spray operates within the therapeutic range between manual intramuscular injection and autoinjectors, and early user experiences have been positive.

The panel also discussed additional products currently in development, including other nasal formulations and a sublingual oral film called Anaphylm, which utilizes a prodrug approach to address epinephrine’s absorption challenges. Dr. Jay Lieberman from the University of Tennessee Health Science Center noted that many patients have a strong preference for oral medications, making a sublingual option particularly appealing if it proves effective. Newer formulations may also offer practical advantages, such as longer shelf life and greater temperature stability.

In conclusion, both Dr. Golden and Dr. Lieberman emphasized the core message of the entire series: improving anaphylaxis outcomes necessitates earlier epinephrine use and fewer barriers to administration. They advocate abandoning the outdated reliance on antihistamines and corticosteroids in acute care situations. As Dr. Lieberman succinctly stated, “Epinephrine, epinephrine. Let’s stop using steroids for anaphylaxis, and let’s use epinephrine early on and get rid of barriers to use.”

The expertise shared by panelists including Brian Schroer, MD, of Cleveland Clinic Children’s Hospital, reflects a growing recognition of the need for innovative approaches in the management of anaphylaxis. This dialogue marks a critical step toward enhancing patient outcomes in urgent care scenarios.